Skip to content
Search AI Powered

Latest Stories

'One year on, no medicine has entered NHSE’s Innovative Medicines Fund'

The NHS England(NHSE) Innovative Medicines Fund (IMF) should be efficiently utilised to expedite patient access to potentially valuable new medications, thereby incentivising the pharmaceutical industry to develop costly drugs for rare diseases, according to medical experts. However, no medicines have entered the fund since its establishment in 2021. Simon Stevens served as the Chief Executive of NHSE during that time.

In their article for the Journal of the Royal Society of Medicine, health economics and policy specialists from the London School of Hygiene & Tropical Medicine (LSHTM) cautioned that mishandling the rollout of the NHSE's IMF may deter vital evidence generation, concurrently shifting the financial onus from the pharmaceutical industry to public finances.


Expanding upon the successful UK Cancer Drugs Fund (CDF), which provided early access to critical medications for over 80,000 patients, the IMF was established with a parallel £340 million yearly budget. This fund aimed to simplify managed access agreements for treatments, including conditions like spinal muscular atrophy.

ABPI’s apprehensions on IMF

In response to the journal's report, the Association of the British Pharmaceutical Industry (ABPI) expressed concerns regarding the Fund's efficacy, particularly the requirement for drug manufacturers to bear the complete treatment costs for fund beneficiaries, even if the UK's health technology assessor subsequently does not endorse the therapy's usage.

Moreover, firms are obligated to reimburse expenses surpassing a yearly budget, the extent of which is autonomously determined by legislators.

"The IMF was established over a year ago to extend managed access to new medicines for patients with various diseases, including rare conditions, while further evidence is gathered," said Paul Catchpole, Director of Value and Access Policy at the Association of the British Pharmaceutical Industry (ABPI).

"To date, no medicines have entered the fund under this premise, and we are keen to collaborate with NHS England and National Institute for Health and Care Excellence (NICE) to comprehensively comprehend the reasons and actively contribute to realising the Fund's potential for patient benefit,” he added.

Accumulated funding pool yielding limited or no results?

Since 2021, the combined funding pool for both the CDF and IMF totals £680 million (£340 million each), dedicated to expediting early access to the most promising medications. However, the experts at LSHTM contend that the CDF and IMF initiatives, acknowledged as 'managed access' schemes, are restricted solely to medications and lack extension to other forms of interventions.

They further argue that the societal value of the CDF remains unclear, highlighting concerns about the transparency of drug costs and the duration of their integration into the scheme. Similarly, the IMF's principles and operational framework are presently confined to documents, yielding restricted or negligible outcomes for NHS patients.

"Although we generally endorse the IMF's eight guiding principles, we find their operationalisation lacking adequate detail and not fully leveraging the CDF experience," said Dr Aris Angelis, Lead Author and Assistant Professor in Health Economics at the Department of Health Services Research and Policy at LSHTM.

"Addressing non-medical interventions gains specific importance in disease domains like cancer, where access to high-quality radiation and surgical treatments plays a pivotal role in enhancing outcomes," said co-author Dr Ajay Aggarwal, Associate Professor at LSHTM and Clinical Oncologist.

Critical need for precise planning

An additional concern underscored by the authors is the entry criteria for 'most promising' medicines into the IMF, which, they contend, are currently deficient in essential details.

For the IMF to effectively facilitate timely access to clinically effective, safe and cost-efficient medicines, the authors assert that meticulous design is imperative for its operational specifics and established mechanisms.

"Parallel to the CDF, the IMF should act as a pathway for patient access, also offering essential evidence—mainly from randomised controlled trials—to address uncertainties about a drug's clinical and cost-effectiveness," Dr Angelis added.

Meanwhile, the NHS reported that over 425,000 patients used its recently launched nationwide online service for completing GP registration. Operated by NHS England, this GP surgery registration service has given NHS patients efficient and easy access to registration since its launch in August 2022.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
It is official: Opella is now a standalone company

Opella launches as an independent company to redefine the future of self-care.

Photo credit: gettyimages

Opella becomes standalone company as Sanofi-CD&R deal closes

Opella has officially become a standalone company, following the completion of Sanofi’s sale of a controlling 50.0% stake to private equity firm Clayton, Dubilier & Rice (CD&R).

Sanofi retains a significant shareholding with a 48.2% stake while Bpifrance holds the remaining 1.8% stake.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less